---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-26-000093"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2026-06-12T21:00:17+00:00"
generated_at: "2026-06-12T21:04:09.183743+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# BioRestorative Therapies extends VP R&D Silva's employment; $575K salary unchanged, term to June 2029

## Summary
- New employment agreement for VP R&D Francisco Silva, effective June 10, 2026, with term through June 10, 2029.
- Salary remains at $575,000 per year; eligible for annual discretionary bonus up to 50% of salary.
- On termination without cause or resignation for good reason, severance equals 1.5x (salary + max bonus), plus COBRA paid for 1.5 years, and full vesting of equity awards.
- Non-compete and non-solicitation covenants apply for 1 year post-termination within US in stem-cell based therapies and biocosmeceuticals.
- Agreement includes assignment of all developments and inventions related to company's business as work made for hire.

## SEC filing metadata
- accession: 0001021771-26-000093
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2026-06-12T21:00:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177126000093/0001021771-26-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177126000093/brtx-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-26-000093
- JSON: https://secwatch.observer/filing/0001021771-26-000093.json
- Plain text: https://secwatch.observer/filing/0001021771-26-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.